论文部分内容阅读
致病性真菌感染是医疗中的重要问题,尤其对免疫功能已受破坏(例如艾滋病)的病人。目前对真菌性疾病的治疗药物主要有两性霉素B、氟胞嘧啶以及咪康唑、酮康唑等氮杂茂类结构药物。氟康唑(fluconazole,商品名Diflucan,Roerig)是新近经FDA批准的新颖氮杂茂类药物,对真菌感染,包括中枢神经感染的治疗效用更好。氟康唑的作用机理与其他氮杂茂类抗真菌药相仿,系抑制麦角甾醇的生物合成,后者为真菌膜上的重要脂质。它特异性地阻断14α-
Pathogenic fungal infections are an important medical problem, especially for patients whose immune function has been compromised (such as AIDS). The current treatment of fungal diseases are amphotericin B, flucytosine and miconazole, ketoconazole and other azole structure drugs. Fluconazole (fluconazole, trade name Diflucan, Roerig) is a new FDA-approved novel azole drug that is more effective in the treatment of fungal infections, including central nervous system infections. The mechanism of action of fluconazole is similar to that of other azole antifungal agents, inhibiting the biosynthesis of ergosterol, which is an important lipid in fungal membranes. It specifically blocks 14α-